EUVIMEDEUVIMED entdecken
Crossref

Aspirin deprescribing in primary prevention of cardiovascular disease: a prospective risk–benefit approach

Nicholas L Scarfo iD, Vinod Thomas, Markian S Mayboroda, Udul Hewage

Internal Medicine Journal · 2023-11 · 53 (11) · 2007-2015

DOI: 10.1111/imj.16079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 24.04.2023. Verfasst von Nicholas L Scarfo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Southern Adelaide Local Health Network (SALHN), Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Deprescriptions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current evidence and practice guidelines do not recommend aspirin for primary prevention of cardiovascular disease (CVD). Insufficient all‐cause mortality benefits juxtaposed to increased gastrointestinal bleeding rates are well established. Pharmacists are well placed to assess the clinical appropriateness of aspirin in CVD and initiate deprescribing as required with medical colleagues.

Aim

The aim of this study was to identify medical inpatients taking aspirin for primary prevention of CVD and initiate deprescribing utilising a risk‐benefit approach.

Methods

A single‐arm prospective feasibility study of general medicine patients admitted to a major tertiary hospital over 5 weeks (July–August 2020) was conducted. Screened patients were categorised as either taking aspirin for primary or secondary prevention. A 5‐year benefit–risk analysis of bleeding and cardiovascular risk was calculated using a validated tool from the Cardiac Society of Australia and New Zealand to guide recommendations.

Results

This study screened 277 patients, of which 71 patients were identified as taking aspirin. Ten of these patients (14%) were categorised as taking aspirin for primary prevention and thus were deemed suitable for deprescribing. The analysis showed that aspirin continuance would, on average, increase major bleeding events by 39%, whilst reducing major cardiovascular events by 13.4%. Pharmacists recommended aspirin cessation in seven of the cases identified, and deprescribing was successful in five cases.

Conclusions

This study described an impactful pharmacist‐led initiative utilising a validated aspirin‐specific tool to conduct risk–benefit analysis to reduce potential major bleeding associated with inappropriate aspirin use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDeprescriptionsHumansAspirinProspective StudiesPrimary PreventionRisk AssessmentGastrointestinal Hemorrhage

Stichwörter der Autor:innen

aspirinbleedingcalculatorcardiovascular diseasedeprescribing

Substanzen

Aspirin

Autor:innen und Institutionen

  • Southern Adelaide Local Health Network (SALHN), Adelaide, South Australia, Australia.
  • Central Adelaide Local Health Network (CALHN), Adelaide, South Australia, Australia.

ORCID-Profile: Nicholas L Scarfo

Zitieren

APA

Scarfo, N. L., Thomas, V., Mayboroda, M. S., & Hewage, U. (2023). Aspirin deprescribing in primary prevention of cardiovascular disease: a prospective risk–benefit approach. Internal Medicine Journal, 53(11), 2007-2015. https://doi.org/10.1111/imj.16079

Vancouver

Scarfo NL, Thomas V, Mayboroda MS, Hewage U. Aspirin deprescribing in primary prevention of cardiovascular disease: a prospective risk–benefit approach. Internal Medicine Journal. 2023;53(11):2007-2015. doi:10.1111/imj.16079

BibTeX
@article{Scarfo2023,
  author = {Scarfo, Nicholas L and Thomas, Vinod and Mayboroda, Markian S and Hewage, Udul},
  title = {Aspirin deprescribing in primary prevention of cardiovascular disease: a prospective risk–benefit approach},
  journal = {Internal Medicine Journal},
  year = {2023},
  volume = {53},
  number = {11},
  pages = {2007--2015},
  doi = {10.1111/imj.16079}
}
Kostenlos starten →